The Lancet
@TheLancet
Followers
735K
Following
10K
Media
10K
Statuses
27K
Welcome to The Lancet, one of the world’s leading medical journals, published weekly since 1823.
London, New York, Beijing
Joined March 2009
Heart failure affects more than 55 million people worldwide. 🫀 . A new Lancet Series, presented at #ESC2025, serves as a call to action for clinicians, health systems, and governments to prioritise the primary prevention of heart failure.
4
60
169
Case management of enteric fever is challenging due to clinical presentation overlaps, unreliable diagnostic tests, & widespread AMR. A new Seminar explores the evidence supporting effective case management of patients with suspected enteric fever:
0
5
5
There is growing interest in the study of postpartum anxiety, but the field has been challenged by a lack of studies. A new Review provides an overview of current literature, highlights existing knowl edge gaps, & discusses directions for future research:
0
11
35
RT @TheLancetHaem: 🩸September issue!. Cost-effective targets to reduce anaemia, costs of anaemia interventions, ferritin-guided iron supple….
0
4
0
Antimicrobial resistance (AMR) disproportionately affects people who are immunocompromised. In @TheLancetInfDis, authors discuss opportunities to enhance use of diagnostic tools and digital innovation—to optimise antibiotic use and the potential for precision medicine approaches
2
17
30
Every year, The Lancet holds a Wakley Prize competition. Is this your year to enter? ✍️. Find out what we’re looking for ⤵️
0
2
10
RT @TheLancetOncol: 🔴Now live: Establishing the China–UK Cancer Prevention and Control Alliance. UK and China representatives discuss estab….
0
7
0
RT @TheLancetOncol: Celebrating 25 years since our first issue, our editorial discusses The Lancet Oncology's inception, values, and future….
0
2
0
RT @TheLancetOncol: 🚨Our Sept issue is live - 25 years! 📊Articles #renalcellcarcinoma, #prostatecancer, #meningiom….
0
6
0
"Why are we failing to rapidly diagnose tuberculosis in the UK?". Authors explore this question in a new letter ⤵️
2
3
9
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. In @LancetGastroHep, a new Personal View proposes a comprehensive and multisectoral approach for the sustainable management of MASLD:
1
71
231
Bipolar disorder affects over 40 million people worldwide. Yet diagnosis remains challenging, causing delays in effective treatment. Recent advances in understanding & emerging therapies offer hope for more precise, patient-centred care. Find out more:
thelancet.com
The hallmark of bipolar disorder is hypomania or mania, and the predominant phase of illness is depression. Affecting approximately 40 million individuals worldwide, bipolar disorder is associated...
0
13
36
Presenting at #ESCCongress: Clopidogrel more effective than aspirin for long-term heart disease prevention without added bleeding risk, new study finds
thelancet.com
These findings add to the evidence that clopidogrel monotherapy is superior to aspirin monotherapy for MACCE prevention with no increase in the risk of bleeding, and support the preferential use of...
2
40
114
"By working together, we will accelerate progress towards a better understanding of cardiovascular medicine and improve outcomes for individual patients and population health.". The Lancet–@JACCJournals collaboration: advancing cardiovascular health ⤵️.
thelancet.com
Preventing, diagnosing, and managing cardiovascular disease stands as one of the most pressing and pivotal global health challenges of our time. Despite decades of medical advancements, cardiovascu...
0
12
37
Presenting at #ESCCongress: Intensive blood pressure control can reduce risk of heart attack and stroke, new study confirms
0
4
14
Presenting at #ESCCongress: Immediate versus staged complete revascularisation during index admission in patients with ST-segment elevation myocardial infarction and multivessel disease (OPTION–STEMI): a multicentre, non-inferiority, open-label, randomised trial.
1
0
8
Presenting at #ESCCongress: Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in chronic limb-threatening ischaemia (SWEDEPAD 1): a multicentre, participant-masked, registry-based, randomised controlled trial
thelancet.com
In patients with chronic limb-threatening ischaemia undergoing infrainguinal endovascular revascularisation, paclitaxel-coated devices did not reduce major ipsilateral amputations.
0
2
19
Presenting at #ESCCongress: Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in patients with intermittent claudication (SWEDEPAD 2): a multicentre, participant-masked, registry-based, randomised controlled trial
thelancet.com
In patients with Rutherford stage 1–3 peripheral artery disease undergoing infrainguinal endovascular revascularisation, paclitaxel-coated devices did not improve disease-specific quality of life at...
0
1
9
📢 Tomorrow: Save your spot for the @JACCJournals and The Lancet Editors Reception at #ESCCongress 2025!. Meet and mingle with members of the JACC and The Lancet editorial teams. Register here ⤵️ .
0
3
11
43 million lives are lost every year to non-communicable diseases (NCDs), and up to 80% of these deaths could be prevented. Our latest Editorial highlights critical gaps and calls for stronger action to prevent a future overwhelmed by NCDs:
4
37
84
Presenting at #ESCCongress: Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-randomised, controlled trial in China
thelancet.com
Influenza vaccination during a hospital admission in patients with acute heart failure can improve their survival and reduce likelihood of readmission to hospital over the subsequent 12 months. The...
0
5
9